Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma [review of TA658] [ID4067]

Appeal

Myeloma UK/Myeloma Society : Appeal letter (MSWord 44 KB)

Sanofi : Appeal letter (MSWord 76 KB)

Myeloma UK/Myeloma Society : Final scrutiny letter (MSWord 69 KB)

Sanofi : Final scrutiny letter (MSWord 76 KB)

Myeloma UK/Myeloma Society : Scrutiny letter (MSWord 74 KB)

Sanofi : Scrutiny letter (MSWord 49 KB)

Final draft guidance

Final draft guidance (PDF 217 KB)

Public committee slides (PDF 1.08 MB)

Draft guidance

Appraisal consultation document (PDF version) (PDF 257 KB)

Committee papers (PDF 17.83 MB)

Public committee slides (PowerPoint 967 KB)

Appraisal consultation document (online commenting)

Committee meeting: 1

Supporting documentation Register of interests (PDF 172 KB)

Committee meeting: 2

Final scope (PDF 196 KB)

Final stakeholder list (PDF 167 KB)

NICE's response to comments on the draft scope and provisional stakeholder list (PDF 257 KB)